|1.||Samuel, Chrishan S: 45 articles (01/2015 - 11/2002)|
|2.||Bathgate, Ross A D: 25 articles (11/2015 - 01/2003)|
|3.||Tregear, Geoffrey W: 21 articles (05/2011 - 01/2003)|
|4.||Bani, Daniele: 20 articles (06/2015 - 03/2004)|
|5.||Hewitson, Tim D: 14 articles (08/2014 - 03/2004)|
|6.||Unemori, Elaine: 12 articles (10/2014 - 07/2003)|
|7.||Du, Xiao-Jun: 12 articles (06/2014 - 09/2004)|
|8.||Zhao, Chongxin: 12 articles (01/2012 - 01/2003)|
|9.||Nistri, Silvia: 11 articles (06/2015 - 03/2004)|
|10.||Agoulnik, Alexander I: 11 articles (01/2015 - 01/2006)|
03/01/2014 - "The results suggest that relaxin may be an effective treatment for the treatment of established hepatic fibrosis."
05/01/2005 - "In conclusion, both LGR7 and LGR8 are expressed in activated HSCs and cirrhotic liver, suggesting that relaxin, InsL3, or relaxin-3 may be useful in the treatment of hepatic fibrosis."
12/01/2005 - "Relaxin therapy enhanced muscle regeneration, reduced fibrosis, and improved injured muscle strength in vivo. "
08/01/2012 - "Recent studies have shown that relaxin prevents and reverses cardiac fibrosis. "
11/01/2010 - "In addition, our previous study demonstrated that relaxin is beneficial to skeletal muscle healing by both promoting muscle regeneration and preventing fibrosis formation. "
09/01/2013 - "More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. "
11/01/2010 - "The results of phase I and II trials have shown favorable clinical trends without any major adverse events, suggesting that relaxin has the potential to be an effective medication for acute heart failure in conjunction with or in place of current treatments."
03/01/2014 - "The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of human relaxin-2. "
01/01/2015 - "H2 relaxin recently passed Phase III clinical trials for the treatment of congestive heart failure. "
10/14/2014 - "In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF. "
10/15/2013 - "The results demonstrated that relaxin provided protection against IR-induced renal injury by reducing apoptosis and inflammation. "
01/17/2011 - "Our findings identify relaxin as a promising inhibitory factor in early vascular inflammation. "
01/17/2011 - "Relaxin inhibits early steps in vascular inflammation."
05/01/2005 - "The findings indicate that PBMCs should be studied in relation to the effect of relaxin on inflammation and bone destruction caused by osteoclasts."
04/01/2009 - "Wounds in animals receiving systemic relaxin had an improved appearance with less redness, reduced granulation tissue, and lower amounts of inflammation. "
|4.||Wounds and Injuries (Trauma)
09/01/2000 - "In the present study, relaxin's angiogenic effects in the context of wound repair were tested in rodent models of angiogenesis and wound healing. "
09/01/2000 - "Previously conducted clinical studies using partially purified porcine relaxin have described relaxin's ability to stimulate the healing of ischemic wounds, suggesting that relaxin may also have angiogenic effects at sites of ischemic wound healing. "
11/01/2010 - "These results revealed the multiple effects of relaxin in systematically improving muscle healing as well as its potential for clinical applications in patients with skeletal muscle injuries and diseases."
01/01/2009 - "Relaxin may affect the load bearing properties of the female ACL and contribute to non-contact ACL injuries. "
12/01/2005 - "The effect of relaxin treatment on skeletal muscle injuries."
08/01/2006 - "Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion."
01/01/2013 - "Although preclinical and clinical studies have demonstrated that relaxin (RLX) ameliorates impaired renal function by exerting antifibrotic and regenerative effects, its role in renal ischemia/reperfusion (I/R) injury has never been investigated. "
08/01/2006 - "We investigated the effects of relaxin (RLX), known to afford protection against the deleterious effects of cardiac ischemia/reperfusion, given to rats subjected to splanchnic artery occlusion and reperfusion (SAO/R)-induced splanchnic injury. "
01/01/2008 - "In this study, we report on a swine model of heart ischemia/reperfusion, currently used to test cardiotropic drugs, in which human recombinant relaxin (2.5 and 5 microg/kg b.w.), given at reperfusion upon a 30-min ischemia, markedly reduced cardiac injury as compared with the vehicle-treated animals. "
05/01/1998 - "This study shows that relaxin can be regarded as an agent with a marked cardioprotective action against ischemia-reperfusion-induced myocardial injury."
|3.||Nitric Oxide (Nitrogen Monoxide)
|4.||Purinergic P1 Receptors (Adenosine Receptor)
|7.||Brain Natriuretic Peptide (Natrecor)
|8.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)